Rising Clinical Trial Costs: Key Drivers and How Sponsors Can Reduce Expenses

Clinical trials are the core of evidence-based medicine, as they turn scientific results into therapies that improve and extend human life. However, the expense of conducting clinical trials has considerably escalated over the previous few decades, placing even more strain on sponsors, healthcare systems, and eventually patients. Even if some of this rise reflects actual gains like more scientific rigor, improved safety rules, and more individualized therapy, a significant percentage of it is due to structural inefficiencies in the way trials are designed and conducted. It is evident from understanding these cost drivers that both innovation and the structure of the clinical research ecosystem contribute to rising costs.

Research Complexity

One of the primary reasons for the rise in trial expenses is the increasing complexity of research procedures. Modern trials may include a large number of objectives, strict eligibility restrictions, regular assessments, and intricate biomarker analysis. These traits may inadvertently decrease efficiency even though they are commonly employed to further scientific understanding. Patient involvement is hampered, protocol breaches are more likely, and research site operations are burdened by complex procedures.

Each stage results in data that has to be monitored and validated, lengthens visitation durations, and requires staff training. Like an overengineered structure, excessive complexity might include needless points of failure, which would make the system weaker rather than stronger.

A scene of people waiting in a healthcare setting, likely a clinic or hospital.

Participant Recruitment

Recruitment challenges further compound these costs. Eligible patient populations are becoming smaller and harder to reach as medicine shifts toward targeted, precision therapies.

Concurrently, sponsors have increased competition for the same participants, particularly in areas such as cancer and rare disorders. And given one of the most costly issues in clinical research is recruitment delays, this can lead to a chain reaction of events including longer site contracts, higher personnel expenses, and postponed regulatory filings. Furthermore, a high patient load increases dropout rates, which may lead to insufficient data and in certain cases, the necessity to enlist additional participants.

These inefficiencies demonstrate a disconnect between trial design and real patient experience, just like biological systems malfunction when structural components don't match functional requirements.

Site Capacity & Performance

Another significant factor contributing to rising costs is the capacity limitations that clinical trial sites must deal with. Workforce burnout is pervasive, administrative demands have increased, and research coordinators and investigators are more overburdened with numerous projects. Reduced data quality, retraining expenses, and uneven trial execution are all consequences of high staff turnover. Sponsors frequently expand monitoring or add new sites in response to underperforming sites, both of which boost expenses. These reactionary steps frequently conceal more serious structural flaws in site support and planning rather than fortifying the basis of the research process.

Regulatory Requirements

Regulations and compliance requirements have increased trial expenses, despite their importance for participant safety and data integrity. Over time, demands for safety reporting, documentation, and audit preparation have grown. Meeting these standards requires advanced technology, specialized personnel, and extended review timelines.

Importantly, the resulting costs are not only financial but also operational, manifesting as reduced flexibility and delayed study initiation. When a trial becomes unduly procedural rather than goal-oriented, compliance risks diverting focus away from the fundamental scientific concerns it is intended to address.

Complexity of Data Management

Another important element is the abundance of data. Innovations in genetics, imaging, and digital health technologies have made it possible to gather previously unheard-of amounts of data. Better proof, however, does not always follow from greater data.

Validation, integration, and continuous quality control are necessary for every new data stream. Exploratory data is frequently gathered without a defined plan for analysis or decision-making, which adds expense without providing benefit. This is similar to biological settings where too many structural elements might hinder rather than facilitate signaling.

Ways to Mitigate These Challenges

Sponsors are not helpless in spite of these difficulties. A mental change from maximizing data gathering to maximizing decision quality is the first step towards meaningful cost savings. Both direct and indirect expenses can be decreased with careful protocol design that prioritizes important goals while minimizing patient suffering. Early communication between researchers and patients ensures that studies are useful and applicable, which increases enrolment and retention.

By including risk awareness in trial preparation, adopting quality-by-design principles can also assist sponsors in avoiding costly downstream adjustments. By focusing control on critical data and processes rather than meticulously verifying every variable, sponsors may maintain trial integrity while reducing operational waste. When implemented thoughtfully and effectively, technology may further enhance operations by reducing travel, simplifying data collection, and increasing patient participation. But rather than making the trial's framework more difficult, technology must support it.

Enhancing coordination within the clinical trial ecosystem is crucial at a higher level. Reducing duplication and rework may be achieved through long-term partnerships based on performance data, realistic site workloads, and clear accountability across suppliers. 

As myLaminin has onboarded many clinical trial researchers, we learned of these many challenges and set out to address them. To do so, we integrated a new regulatory-compliant Clinical Trial Management System (CTMS) platform into our already powerful Research Data Management (RDM) solution. What this does is provide researchers one contemporary and integrated platform that covers all aspects of clinical trials, and more importantly, it links the important participant tracking and data collection components to the CTMS module with 21 CFR Part 11 compliant eSignature capabilities. Effectively, we have created a new category of clinical trial software - what we believe is a Clinical Research Operating System (CR/os). Through collaboration with several clinical trial support units and leading research institutes, myLaminin is working to facilitate, streamline, secure, and accelerate clinical trials and clinical research.

Ultimately, the rising cost of clinical trials signals a deeper structural misalignment in how research is designed and executed, not merely the cost of scientific progress. By reevaluating study design, finance, and administration, sponsors can cut needless spending while maintaining patient safety and scientific integrity. Similar to how myLaminin offers an integrated framework for clinical trial research data management, a well-organized clinical trial setting could drive innovation while keeping expenses under control. Improving processes that enable key work to be completed with clarity, speed, and rigor is more important for the future of sustainable clinical research than doing more.

CTMS is not just project management software, it is the operational backbone of trusted, compliant, and secure clinical research.

Sources

Agius, S., Cassar, V., Bezzina, F., & Topham, L. (2025). Leveraging digital technologies to enhance patient safety. Health and Technology. https://doi.org/10.1007/s12553-025-01001-6

Assessing Protocol Complexity and its Impact on Trial Outcomes. (2025). Https://Www.iqvia.com/Blogs/2026/01/Assessing-Protocol-Complexity-And-Its-Impact-On-Trial-Outcomes. https://www.iqvia.com/blogs/2026/01/assessing-protocol-complexity-and-its-impact-on-trial-outcomes

Cagnazzo, C., Testoni, S., Speranza, D., Mannozzi, F., Stabile, S., Federici, I., Betti, M., Ferrari, A., Penolazzi, L., & Franchina, V. (2025). The role and challenges of clinical research coordinators: insights from a national survey. BMC Medical Research Methodology, 25(1). https://doi.org/10.1186/s12874-025-02687-y

Cordes, J. (2024). An Expert Guide To Effective Sponsor Oversight In Clinical Trials. Clinicalleader.com. https://www.clinicalleader.com/doc/an-expert-guide-to-effective-sponsor-oversight-in-clinical-trials-0001

Garton, W. (2024, December 23). Elevating Clinical Research Site Relationships With New Budget and Payment Paradigms. Appliedclinicaltrialsonline.com; Applied Clinical Trials Online. https://www.appliedclinicaltrialsonline.com/view/clinical-research-site-relationships-budget-payment-paradigms

Hassan, M., Awan, F. M., Naz, A., deAndrés-Galiana, E. J., Alvarez, O., Cernea, A., Fernández-Brillet, L., Fernández-Martínez, J. L., & Kloczkowski, A. (2022). Innovations in Genomics and Big Data Analytics for Personalized Medicine and Health Care: A Review. International Journal of Molecular Sciences, 23(9), 4645. https://doi.org/10.3390/ijms23094645

Hung, M., Amir Mohajeri, Konstantinia Almpani, Carberry, G., Wisniewski, J. F., Janes, K., Janes, B., Hardy, C., Golnoush Zakeri, Raymond, B., Trinh, H., Bretner, J., Cheever, V. J., Garibyan, R., Bachstein, P., & Licari, F. W. (2024). Successes and Challenges in Clinical Trial Recruitment: The Experience of a New Study Team. Medical Sciences, 12(3), 39–39. https://doi.org/10.3390/medsci12030039

Ilya. (2025, September 15). CRO Perspective: 4 Surprising Reasons Clinical Trials Are So Expensive - Palleos. Palleos. https://www.palleos.com/resource-library/blog/why-clinical-trials-are-so-expensive/

Markey, N., Howitt, B., El-Mansouri, I., Schwartzenberg, C., Kotova, O., & Meier, C. (2024). Clinical trials are becoming more complex: a machine learning analysis of data from over 16,000 trials. Scientific Reports, 14(1), 3514. https://doi.org/10.1038/s41598-024-53211-z

Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., Silva, I., Magalhães, P., Schmidt, S., & Vale, N. (2024). Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. Pharmaceutics, 16(3), 332. https://doi.org/10.3390/pharmaceutics16030332

Takaoka, A., Zytaruk, N., Davis, M., Matte, A., Johnstone, J., Lauzier, F., Marshall, J., Adhikari, N., Clarke, F. J., Rochwerg, B., Lamontagne, F., Hand, L., Watpool, I., Porteous, R. K., Masse, M.-H., D’Aragon, F., Niven, D., Heels-Ansdell, D., Duan, E., & Dionne, J. (2022). Monitoring and auditing protocol adherence, data integrity and ethical conduct of a randomized clinical trial: A case study. Journal of Critical Care, 71, 154094. https://doi.org/10.1016/j.jcrc.2022.154094